ScreenerHero

KURA Kura Oncology, Inc.

NAS · US · Healthcare · Biotechnology · kuraoncology.com
10.67USD+1.33%Mkt Cap: 949.21M $P/E: —

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral sma…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap949.21M USD
Enterprise Value442.19M USD
Revenue (TTM)77.22M USD
Gross Profit67.42M USD
Net Income (TTM)-278.67M USD
Revenue/Share0.88 USD
Last Price10.67 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees260
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.48
PEG—
EV/EBITDA-1.40
EV/Revenue5.73
P/S12.13
P/B19.36
EPS (TTM)-3.37
EPS (Forward)-2.35
52W Range
7.35853% of range13.66
52W High13.66 USD
52W Low7.358 USD
Profitability
Gross Margin99.92%
Oper. Margin-349.77%
EBITDA Margin0.00%
Profit Margin-412.95%
ROE-160.03%
ROA-37.74%
Growth
Revenue Growth36.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-64.06M USD
CapEx (TTM)6.64M USD
FCF Margin-214.80%
FCF Yield-17.48%
Net Debt-494.57M USD
Net Debt/EBITDA1.56
Balance Sheet
Debt/Equity0.12
Current Ratio4.73
Quick Ratio4.50
Book Value/Sh0.54 USD
Cash/Share5.83 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)31.85 USD
Upside (mean)+198.5%
Target Range15.00 USD – 76.00 USD
15.00+198.5% to mean76.00
# Analysts13
Ownership
Shares Out.88.96M
Float70.53M
Insiders1.40%
Institutions100.08%
Short Interest
Short Ratio6.4d
Short % Float17.10%
Short % Out.16.66%
Shares Short14.82M
Short (prev mo.)13.12M
Technical
SMA 5011.18 (-4.5%)
SMA 2009.806 (+8.8%)
Beta0.47
S&P 52W Chg16.45%
Avg Vol (30d)1.90M
Avg Vol (10d)1.85M
Technical Indicators
RSI (14)42.8
MACD-0.2223
MACD Signal-0.1170
MACD Hist.-0.1053
BB Upper12.32 USD
BB Middle11.17 USD
BB Lower10.02 USD
BB Width20.62%
ATR (14)0.5374 USD
Vol Ratio (20d)0.61x